

This is a preview of "DS/EN ISO 22367:2020". [Click here to purchase the full version from the ANSI store.](#)

Medicinske laboratorier – Anvendelse af risikoledeelse i medicinske laboratorier

Medical laboratories – Application of risk management to medical laboratories (ISO 22367:2020)

DANSK STANDARD
Danish Standards Association

Göteborg Plads 1
DK-2150 Nordhavn

Tel: +45 39 96 61 01
dansk.standard@ds.dk
www.ds.dk

This is a preview of "DS/EN ISO 22367:2020". Click here to purchase the full version from the ANSI store.

DS projekt: M329597

ICS: 11.100.01

Første del af denne publikations betegnelse er:

DS/EN ISO, hvilket betyder, at det er en international standard, der har status både som europæisk og dansk standard.

Denne publikations overensstemmelse er:

IDT med: ISO 22367:2020

IDT med: EN ISO 22367:2020

DS-publikationen er på engelsk.

Denne publikation erstatter: [DS/CEN ISO/TS 22367:2010](#)

DS-publikationstyper

Dansk Standard udgiver forskellige publikationstyper.

Typen på denne publikation fremgår af forsiden.

Der kan være tale om:

Dansk standard

- standard, der er udarbejdet på nationalt niveau, eller som er baseret på et andet lands nationale standard, eller
- standard, der er udarbejdet på internationalt og/eller europæisk niveau, og som har fået status som dansk standard

DS-information

- publikation, der er udarbejdet på nationalt niveau, og som ikke har opnået status som standard, eller
- publikation, der er udarbejdet på internationalt og/eller europæisk niveau, og som ikke har fået status som standard, fx en teknisk rapport, eller
- europæisk præstandard

DS-håndbog

- samling af standarder, eventuelt suppleret med informativt materiale

DS-hæfte

- publikation med informativt materiale

Til disse publikationstyper kan endvidere udgives

- tillæg og rettelsesblade

DS-publikationsform

Publikationstyperne udgives i forskellig form som henholdsvis

- fuldtekstpublikation (publikationen er trykt i sin helhed)
- godkendelsesblad (publikationen leveres i kopi med et trykt DS-omslag)
- elektronisk (publikationen leveres på et elektronisk medie)

DS-betegnelse

Alle DS-publikationers betegnelse begynder med DS efterfulgt af et eller flere præfikser og et nr., fx **DS 383**, **DS/EN 5414** osv. Hvis der efter nr. er angivet et **A** eller **Cor**, betyder det, enten at det er et **tillæg** eller et **rettelsesblad** til hovedstandard, eller at det er indført i hovedstandard.

DS-betegnelse angives på forsiden.

Overensstemmelse med anden publikation:

Overensstemmelse kan enten være IDT, EQV, NEQ eller MOD

- **IDT:** Når publikationen er identisk med en given publikation.
- **EQV:** Når publikationen teknisk er i overensstemmelse med en given publikation, men præsentationen er ændret.
- **NEQ:** Når publikationen teknisk eller præsentationsmæssigt ikke er i overensstemmelse med en given standard, men udarbejdet på baggrund af denne.
- **MOD:** Når publikationen er modificeret i forhold til en given publikation.

This is a preview of "DS/EN ISO 22367:2020". [Click here to purchase the full version from the ANSI store.](#)

EUROPÄISCHE NORM

March 2020

ICS 11.100.01

Supersedes CEN ISO/TS 22367:2010

English Version

Medical laboratories - Application of risk management to medical laboratories (ISO 22367:2020)

Laboratoires de biologie médicale - Application
de la gestion des risques aux laboratoires
de biologie médicale (ISO 22367:2020)

Medizinische Laboratorien - Fehlerverringerng
durch Risikomanagement und ständige
Verbesserung (ISO 22367:2020)

This European Standard was approved by CEN on 7 February 2020.

CEN members are bound to comply with the CEN/CENELEC Internal Regulations which stipulate the conditions for giving this European Standard the status of a national standard without any alteration. Up-to-date lists and bibliographical references concerning such national standards may be obtained on application to the CEN-CENELEC Management Centre or to any CEN member.

This European Standard exists in three official versions (English, French, German). A version in any other language made by translation under the responsibility of a CEN member into its own language and notified to the CEN-CENELEC Management Centre has the same status as the official versions.

CEN members are the national standards bodies of Austria, Belgium, Bulgaria, Croatia, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Iceland, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, Netherlands, Norway, Poland, Portugal, Republic of North Macedonia, Romania, Serbia, Slovakia, Slovenia, Spain, Sweden, Switzerland, Turkey and United Kingdom.



EUROPEAN COMMITTEE FOR STANDARDIZATION
COMITÉ EUROPÉEN DE NORMALISATION
EUROPÄISCHES KOMITEE FÜR NORMUNG

CEN-CENELEC Management Centre: Avenue Marnix 17, B-1000 Brussels

This is a preview of "DS/EN ISO 22367:2020". [Click here to purchase the full version from the ANSI store.](#)

Contents

Page

European foreword	3
-------------------------	---

This is a preview of "DS/EN ISO 22367:2020". [Click here to purchase the full version from the ANSI store.](#)

European foreword

This document ([EN ISO 22367:2020](#)) has been prepared by Technical Committee ISO/TC 212 "Clinical laboratory testing and in vitro diagnostic test systems" in collaboration with Technical Committee CEN/TC 140 "In vitro diagnostic medical devices" the secretariat of which is held by DIN.

This European Standard shall be given the status of a national standard, either by publication of an identical text or by endorsement, at the latest by September 2020, and conflicting national standards shall be withdrawn at the latest by September 2020.

Attention is drawn to the possibility that some of the elements of this document may be the subject of patent rights. CEN shall not be held responsible for identifying any or all such patent rights.

This document supersedes CEN [ISO/TS 22367:2010](#).

According to the CEN-CENELEC Internal Regulations, the national standards organizations of the following countries are bound to implement this European Standard: Austria, Belgium, Bulgaria, Croatia, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Iceland, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, Netherlands, Norway, Poland, Portugal, Republic of North Macedonia, Romania, Serbia, Slovakia, Slovenia, Spain, Sweden, Switzerland, Turkey and the United Kingdom.

Endorsement notice

The text of [ISO 22367:2020](#) has been approved by CEN as [EN ISO 22367:2020](#) without any modification.

This is a preview of "DS/EN ISO 22367:2020". [Click here to purchase the full version from the ANSI store.](#)

This is a preview of "DS/EN ISO 22367:2020". [Click here to purchase the full version from the ANSI store.](#)

First edition
2020-02-25

Medical laboratories — Application of risk management to medical laboratories

*Laboratoires de biologie médicale — Application de la gestion des
risques aux laboratoires de biologie médicale*



Reference number
ISO 22367:2020(E)

© ISO 2020

This is a preview of "DS/EN ISO 22367:2020". [Click here to purchase the full version from the ANSI store.](#)



COPYRIGHT PROTECTED DOCUMENT

© ISO 2020, Published in Switzerland

All rights reserved. Unless otherwise specified, no part of this publication may be reproduced or utilized otherwise in any form or by any means, electronic or mechanical, including photocopying, or posting on the internet or an intranet, without prior written permission. Permission can be requested from either ISO at the address below or ISO's member body in the country of the requester.

ISO copyright office
Ch. de Blandonnet 8 • CP 401
CH-1214 Vernier, Geneva, Switzerland
Tel. +41 22 749 01 11
Fax +41 22 749 09 47
copyright@iso.org
www.iso.org

This is a preview of "DS/EN ISO 22367:2020". Click here to purchase the full version from the ANSI store.

Contents

Page

Foreword	v
Introduction	vi
1 Scope	1
2 Normative references	1
3 Terms and definitions	1
4 Risk management	9
4.1 Risk management process	9
4.2 Management responsibilities	9
4.3 Qualification of personnel.....	10
4.4 Risk management plan.....	10
4.4.1 General.....	10
4.4.2 Scope of the plan.....	11
4.4.3 Contents of the plan	11
4.4.4 Revisions to the plan	11
4.4.5 Risk management documentation.....	12
5 Risk analysis	12
5.1 General.....	12
5.2 Risk analysis process and documentation	13
5.3 Intended medical laboratory use and reasonably foreseeable misuses.....	13
5.4 Identification of characteristics related to safety	13
5.5 Identification of hazards.....	13
5.6 Identification of potentially hazardous situations.....	14
5.7 Identification of foreseeable patient harms.....	14
5.8 Estimation of the risk(s) for each hazardous situation.....	14
6 Risk evaluation	15
6.1 Risk acceptability criteria.....	15
6.2 Risk evaluation process.....	16
7 Risk control	16
7.1 Risk control options.....	16
7.2 Risk control verification.....	17
7.3 Role of standards in risk control.....	17
7.4 Role of IVD medical devices in risk control.....	17
7.5 Risks arising from risk control measures	17
7.6 Residual risk evaluation.....	17
8 Benefit-risk analysis	18
9 Risk management review	18
9.1 Completeness of risk control.....	18
9.2 Evaluation of overall residual risk.....	18
9.3 Risk management report.....	19
10 Risk monitoring, analysis and control activities	19
10.1 Surveillance procedure.....	19
10.2 Internal sources of risk information	20
10.3 External sources of risk information	20
10.4 Immediate actions to reduce risk	20
Annex A (informative) Implementation of risk management within the quality management system	22
Annex B (informative) Developing a risk management plan	32
Annex C (informative) Risk acceptability considerations	34

This is a preview of "DS/EN ISO 22367:2020". [Click here to purchase the full version from the ANSI store.](#)

Annex D (informative) Identification of characteristics related to safety	37
Annex E (informative) Examples of hazards, foreseeable sequences of events and hazardous situations	44
Annex F (informative) Nonconformities potentially leading to significant risks	53
Annex G (informative) Risk analysis tools and techniques	61
Annex H (informative) Risk analysis of foreseeable user actions	66
Annex I (informative) Methods of risk assessment, including estimation of probability and severity of harm	70
Annex J (informative) Overall residual risk evaluation and risk management review	76
Annex K (informative) Conducting a benefit-risk analysis	78
Annex L (informative) Residual risk(s)	81
Bibliography	82

This is a preview of "DS/EN ISO 22367:2020". [Click here to purchase the full version from the ANSI store.](#)

Foreword

ISO (the International Organization for Standardization) is a worldwide federation of national standards bodies (ISO member bodies). The work of preparing International Standards is normally carried out through ISO technical committees. Each member body interested in a subject for which a technical committee has been established has the right to be represented on that committee. International organizations, governmental and non-governmental, in liaison with ISO, also take part in the work. ISO collaborates closely with the International Electrotechnical Commission (IEC) on all matters of electrotechnical standardization.

The procedures used to develop this document and those intended for its further maintenance are described in the ISO/IEC Directives, Part 1. In particular the different approval criteria needed for the different types of ISO documents should be noted. This document was drafted in accordance with the editorial rules of the ISO/IEC Directives, Part 2 (see www.iso.org/directives).

Attention is drawn to the possibility that some of the elements of this document may be the subject of patent rights. ISO shall not be held responsible for identifying any or all such patent rights. Details of any patent rights identified during the development of the document will be in the Introduction and/or on the ISO list of patent declarations received (see www.iso.org/patents).

Any trade name used in this document is information given for the convenience of users and does not constitute an endorsement.

For an explanation on the voluntary nature of standards, the meaning of ISO specific terms and expressions related to conformity assessment, as well as information about ISO's adherence to the World Trade Organization (WTO) principles in the Technical Barriers to Trade (TBT) see the following URL: www.iso.org/iso/foreword.html.

This document was prepared by Technical Committee ISO/TC 212, *Clinical laboratory testing and in vitro diagnostic test systems*.

This first edition cancels and replaces (ISO/TS 22367:2008) which has been technically revised. [It also incorporates the Technical corrigendum ISO/TS 22367:2008/Cor.1:2009]. The main changes compared to the previous edition are as follows:

- Change in title to indicate this document focusses on the complete risk management cycle for all processes in the medical laboratory. The part on continual improvement is left out;
- The numbering of the clauses is in accordance with the formal risk management process as indicated in [Figure 1](#);
- The content is as far as possible in agreement with the approach used in ISO 14971 Medical devices -Application of risk management to medical devices;
- The relation with ISO 15189:2012 is indicated in Annex A in which [Figure A.1](#) provides a flow chart which indicates how to apply risk management in the laboratory;
- Addition of 10 new annexes, all informative, providing valuable information about the different processes in the risk management cycle without demanding more than justified for the specific purpose;
- [Annex F](#) provides an extensive list of aspects which could be considered as source for risks in the different types of medical laboratories.

Any feedback or questions on this document should be directed to the user's national standards body. A complete listing of these bodies can be found at www.iso.org/members.html.

This is a preview of "DS/EN ISO 22367:2020". [Click here to purchase the full version from the ANSI store.](#)

Introduction

This document provides medical laboratories with a framework within which experience, insight and judgment are applied to manage the risks associated with laboratory examinations. The risk management process spans the complete range of medical laboratory services: pre-examination, examination and post-examination processes, including the design and development of laboratory examinations.

[ISO 15189](#) requires that medical laboratories review their work processes, evaluate the impact of potential failures on examination results, modify the processes to reduce or eliminate the identified risks, and document the decisions and actions taken. This document describes a process for managing these safety risks, primarily to the patient, but also to the operator, other persons, equipment and other property, and the environment. It does not address business enterprise risks, which are the subject of [ISO 31000](#).

Medical laboratories often rely on the use of in vitro medical devices to achieve their quality objectives. Thus, risk management has to be a shared responsibility between the IVD manufacturer and the medical laboratory. Since most IVD manufacturers have already implemented [ISO 14971:2007](#), "Medical devices -Application of risk management to medical devices," this standard has adopted the same concepts, principles and framework to manage the risks associated with the medical laboratory.

Activities in a medical laboratory can expose patients, workers or other stakeholders to a variety of hazards, which can lead directly or indirectly to varying degrees of harm. The concept of risk has two components:

- a) the probability of occurrence of harm;
- b) the consequence of that harm, that is, how severe the harm might be.

Risk management is complex because each stakeholder may place a different value on the risk of harm. Alignment of this standard with ISO 14971 and the guidance of the Global Harmonization Task Force (GHTF) is intended to improve risk communication and cooperation among laboratories, IVD manufacturers, regulatory authorities, accreditation bodies and other stakeholders for the benefit of patients, laboratories and the public health.

Medical laboratories have traditionally focused on detecting errors, which are often the consequence of use errors during routine activities. Use errors can result from a poorly designed instrument interface, or reliance on inadequate information provided by the manufacturer. They can also result from reasonably foreseeable misuse, such as intentional disregard of an IVD manufacturer's instructions for use, or failure to follow generally accepted medical laboratory practices. These errors can cause or contribute to hazards, which may manifest themselves immediately as a single event, or may be expressed multiple times throughout a system, or may remain latent until other contributory events occur. The emerging field of usability engineering addresses all of these 'human factors' as preventable 'use errors.' In addition, laboratories also have to contend with occasional failures of their IVD medical devices to perform as intended. Regardless of their cause, risks created by device malfunctions and use errors can be actively managed.

Risk management interfaces with quality management at many points in [ISO 15189](#), in particular complaint management, internal audit, corrective action, preventive action, safety checklist, quality control, management review and external assessment, both accreditation and proficiency testing. Management of risk also coincides with the management of safety in the medical laboratories, as exemplified by the safety audit checklists in [ISO 15190](#).

Risk management is a planned, systematic process that is best implemented through a structured framework. This standard is intended to assist medical laboratories with the integration of risk management into their routine organization, operation and management.

This is a preview of "DS/EN ISO 22367:2020". [Click here to purchase the full version from the ANSI store.](#)

Medical laboratories — Application of risk management to medical laboratories

1 Scope

This document specifies a process for a medical laboratory to identify and manage the risks to patients, laboratory workers and service providers that are associated with medical laboratory examinations. The process includes identifying, estimating, evaluating, controlling and monitoring the risks.

The requirements of this document are applicable to all aspects of the examinations and services of a medical laboratory, including the pre-examination and post-examination aspects, examinations, accurate transmission of test results into the electronic medical record and other technical and management processes described in [ISO 15189](#).

This document does not specify acceptable levels of risk.

This document does not apply to risks from post-examination clinical decisions made by healthcare providers.

This document does not apply to the management of risks affecting medical laboratory enterprises that are addressed by [ISO 31000](#), such as business, economic, legal, and regulatory risks.

2 Normative references

There are no normative references in this document.